Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | TTBK1 | Q5TCY1 | 5/20 | 0.41 |
| ▸ | TTBK2 | Q6IQ55 | 5/20 | 0.41 |
| ▸ | JAK3 | P52333 | 4/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14894293 | 0.82 | JAK2 (0.41) | JAK2AKT2GSK3BTTBK1TTBK2 | |
| SCHEMBL24345975 | 0.78 | AKT2 (0.50) | JAK2AKT2GSK3BTTBK1TTBK2 | |
| SCHEMBL14355258 | 0.77 | JAK2 (0.47) | JAK2AKT2GSK3BTTBK1TTBK2 | |
| Hydrochloric Acid SCHEMBL4974811 | 0.77 | AKT2 (0.49) | JAK2AKT2GSK3BTTBK1TTBK2 | |
| SCHEMBL4006768 | 0.77 | TTBK1 (0.48) | JAK2AKT2GSK3BTTBK1TTBK2 | |
| SCHEMBL20220690 | 0.74 | TTBK1 (0.49) | JAK2AKT2GSK3BTTBK1TTBK2 | |
| SCHEMBL14907971 | 0.72 | PRKCI (0.49) | JAK2JAK3CSF1R | |
| SCHEMBL12561826 | 0.72 | JAK3 (0.44) | JAK2AKT2GSK3BTTBK1TTBK2 | |
| SCHEMBL24262375 | 0.71 | NOTUM (0.57) | JAK2GSK3BTTBK1TTBK2JAK3 | |
| SCHEMBL8929582 | 0.71 | CDC7 (0.57) | JAK2TTBK1TTBK2JAK3CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20140296204-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140296204-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| WO-2013062945-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296204-A1 | CHEMICAL COMPOUNDS | DNMT1, DNMT3A, DNMT3B | JAK2 381/4885AKT2 1487/4885GSK3B 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.